iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This open-label, randomized, parallel group phase II study will investigate the efficacy of computational biology-informed treatment vs. standard of care treatment for patients with relapsed or refractory myelodysplastic syndromes (MDS).
Epistemonikos ID: 7459c07f0648e4cb359f2026fbb0a8b744c92940
First added on: May 21, 2024